HUTCHMED (00013) announced that the results of the SACHI Phase III study have been published in The Lancet.

SACHI is a Phase III study evaluating the combination therapy of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) for the treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients with MET amplification following disease progression after first-line EGFR tyrosine kinase inhibitor therapy.

Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

Osimertinib is an irreversible, third-generation EGFR TKI.

Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.

Professor Lu Shun, Co-Principal Investigator of the SACHI study and Director of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, stated: "The SACHI study data, now published in The Lancet, provide robust evidence that the combination of savolitinib and osimertinib significantly improves treatment outcomes for EGFR-mutated NSCLC patients with MET amplification.

These results underscore the combination therapy's ability to address MET amplification, a key resistance mechanism, offering clinically meaningful improvements for this challenging patient population.

We are particularly encouraged that consistent efficacy was also observed in patients previously treated with a third-generation EGFR TKI.

The savolitinib and osimertinib combination provides a sustained, all-oral regimen, offering a convenient and well-tolerated treatment option for patients in urgent need of new therapies."

Professor Wang Jie from the Chinese Academy of Medical Sciences Cancer Hospital is also a Co-Principal Investigator of the SACHI study.